{"product_id":"tnm-supplement-isbn-9781119263937","title":"TNM Supplement","description":"\u003cp\u003eThe Union for International Cancer Control�s (UICC) TNM classification system is the most widely used cancer classification and staging system in the world. It is used to describe the anatomical extent of disease and it is essential to patient care, research and cancer control.\u003c\/p\u003e   \u003cp\u003eThis fifth edition of the \u003ci\u003eTNM Supplement: A Commentary of Uniform Use\u003c\/i\u003e offers practitioners a wealth of material intended to complement the system�s day-to-day use. The volume features:\u003c\/p\u003e  \u003cul\u003e \u003cli\u003eUpdated definitions of terms used in cancer staging.\u003c\/li\u003e \u003cli\u003eNew sections on carcinomas of the thymus, sarcomas of the spine and pelvis and soft tissue sarcomas of the head and neck, and comprehensive updates to the head and neck carcinomas, carcinomas of the lung and neuroendocrine tumours sections.\u003c\/li\u003e  \u003cli\u003eFrequently asked questions from the UICC helpdesk.\u003c\/li\u003e  \u003c\/ul\u003e  \u003cp\u003eThe \u003ci\u003eSupplement\u003c\/i\u003e may be treated as a companion text to the recent eighth edition of the \u003ci\u003eTNM Classification of Malignant Tumours\u003c\/i\u003e (978-1-119-26357-9), supporting the correct and uniform application of the TNM classification system. The \u003ci\u003eTNM Supplement\u003c\/i\u003e can also be utilised as a standalone book, providing explanations and examples to answer many questions that arise during the daily use of the TNM cancer classification and staging system, particularly in unusual cases.\u003c\/p\u003eDas TNM-Klassifizierungssystem der Union for International Cancer Controls (UICC) ist das weltweit am meisten eingesetzte Klassifizierungs- und Staging-System. Es beschreibt das anatomische Ausmaß der Krankheit und ist für die Patientenversorgung, die Forschung und Krebskontrolle maßgebend.\u003cbr\u003e Die 5. Auflage von TNM Supplement: A Commentary of Uniform Use bietet Medizinern eine Fülle von Informationen als Ergänzung im Klinikalltag. \u003cbr\u003e - Aktualisierte Definitionen zu Begriffen aus dem Krebs-Staging.\u003cbr\u003e - Neue Abschnitte zu Karzinomen der Thymusdrüse, Sarkomen der Wirbelsäule und des Beckens, Weichteil-Sarkomen von Kopf und Nacken, umfassende Überarbeitungen der Inhalte zu Kopf- und Nackenkarzinomen, Lungenkarzinomen und neuroendokrinen Turmoren.\u003cbr\u003e - FAQ aus der Hotline der UICC.\u003cbr\u003e \u003cbr\u003e Die Ergänzung kann durchaus als Begleitpublikation zur neuen 8. Auflage von TNM Classification of Malignant Tumours (978-1-119-26357-9) dienen, die die korrekte und einheitliche Anwendung des TNM-Klassifizierungssystem unterstützt. Weiterhin lässt es sich als eigenständiges Referenzwerk nutzen mit Erläuterungen und Beispielen zu vielen Fragestellungen, die beim täglichen Einsatz des TNM-Krebsklassifizierungssystem sowie des Staging-Systems auftauchen, insbesondere bei nicht alltäglichen Fällen.\u003cbr\u003e \u003cp\u003ePreface viii\u003c\/p\u003e \u003cp\u003eOrganizations Associated with the TNM System xiii\u003c\/p\u003e \u003cp\u003eNational Committees xiii\u003c\/p\u003e \u003cp\u003eAcknowledgements xv\u003c\/p\u003e \u003cp\u003eAbbreviations xvi\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 1 Explanatory Notes – General\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eThe General Rules of the TNM System 1\u003c\/p\u003e \u003cp\u003eThe TNM Clinical and Pathological Classifications 7\u003c\/p\u003e \u003cp\u003eResidual Tumour (R) Classification 15\u003c\/p\u003e \u003cp\u003eAdditional Descriptors 20\u003c\/p\u003e \u003cp\u003eOptional Descriptors 24\u003c\/p\u003e \u003cp\u003eUnknown Primary 25\u003c\/p\u003e \u003cp\u003eStaging of Tumours for Which No TNM Classification is Provided 25\u003c\/p\u003e \u003cp\u003eHistopathological Grading 26\u003c\/p\u003e \u003cp\u003eReferences 28\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 2 Explanatory Notes – Specific Anatomical Sites\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eHead and Neck Tumours 34\u003c\/p\u003e \u003cp\u003eDigestive System Tumours 54\u003c\/p\u003e \u003cp\u003eLung, Pleural and Thymic Tumours 85\u003c\/p\u003e \u003cp\u003eBone Tumours 104\u003c\/p\u003e \u003cp\u003eSoft Tissue Tumours 106\u003c\/p\u003e \u003cp\u003eGastrointestinal Stromal Tumour (GIST) 108\u003c\/p\u003e \u003cp\u003eSkin Tumours 110\u003c\/p\u003e \u003cp\u003eBreast Tumours 118\u003c\/p\u003e \u003cp\u003eGynaecological Tumours 122\u003c\/p\u003e \u003cp\u003eUrological Tumours 131\u003c\/p\u003e \u003cp\u003eOphthalmic Tumours 142\u003c\/p\u003e \u003cp\u003eHodgkin and Non‐Hodgkin Lymphomas 149\u003c\/p\u003e \u003cp\u003eReferences 150\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 3 Site‐Specific Requirements for pT and pN\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 157\u003c\/p\u003e \u003cp\u003eHead and Neck Tumours 160\u003c\/p\u003e \u003cp\u003eDigestive System Tumours 166\u003c\/p\u003e \u003cp\u003eLung and Pleural Tumours 173\u003c\/p\u003e \u003cp\u003eTumours of Bone and Soft Tissues 176\u003c\/p\u003e \u003cp\u003eSkin Tumours 179\u003c\/p\u003e \u003cp\u003eBreast Tumours 183\u003c\/p\u003e \u003cp\u003eGynaecological Tumours 185\u003c\/p\u003e \u003cp\u003eUrological Tumours 188\u003c\/p\u003e \u003cp\u003eAdrenal Cortex Tumours 192\u003c\/p\u003e \u003cp\u003eOphthalmic Tumours 193\u003c\/p\u003e \u003cp\u003eHodgkin and Non‐Hodgkin Lymphomas 195\u003c\/p\u003e \u003cp\u003eReferences 196\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 4 New TNM Classifications Recommended for Testing and Other Classifications\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 198\u003c\/p\u003e \u003cp\u003eGeneral 198\u003c\/p\u003e \u003cp\u003eSpecific 198\u003c\/p\u003e \u003cp\u003eNon Upper Aerodigestive Tract Mucosal Melanoma 199\u003c\/p\u003e \u003cp\u003ePrimary Liver Carcinoma of Infants and Children\/Hepatoblastoma 200\u003c\/p\u003e \u003cp\u003ePrimary Cutaneous Lymphomas 202\u003c\/p\u003e \u003cp\u003eCutaneous T‐Cell Lymphomas 202\u003c\/p\u003e \u003cp\u003ePrimary Cutaneous Lymphomas 203\u003c\/p\u003e \u003cp\u003eHistopathologic Staging of Lymph Nodes in Mycosis Fungoides and Sézary Syndrome 204\u003c\/p\u003e \u003cp\u003ePrimary Cutaneous B‐Cell\/T‐Cell Lymphoma (Non‐MF\/SS Lymphoma) 206\u003c\/p\u003e \u003cp\u003eMultiple Myeloma 207\u003c\/p\u003e \u003cp\u003eLeukaemia 208\u003c\/p\u003e \u003cp\u003eReferences 208\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 5 Optional Proposals for Testing New Subcategories of TNM\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eAll Tumour Sites 210\u003c\/p\u003e \u003cp\u003eHead and Neck Tumours 210\u003c\/p\u003e \u003cp\u003eDigestive System Tumours 211\u003c\/p\u003e \u003cp\u003eLung Tumours 213\u003c\/p\u003e \u003cp\u003eBreast Tumours (ICD‐0‐3 C50) 214\u003c\/p\u003e \u003cp\u003eGynaecological Tumours 215\u003c\/p\u003e \u003cp\u003eUrological Tumours 215\u003c\/p\u003e \u003cp\u003eReferences 216\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 6 Frequently Asked Questions \u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eGeneral Questions 218\u003c\/p\u003e \u003cp\u003eSite‐Specific Questions 229\u003c\/p\u003e \u003cp\u003eReferences 289\u003c\/p\u003e \u003cp\u003eIndex 291\u003c\/p\u003e \u003cp\u003ePlate section facing p. 48\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChristian Wittekind\u003c\/b\u003e, MD; Professor of Pathology, Chairman Institute of Pathology, University of Leipzig, Germany.\u003c\/p\u003e \u003cp\u003e\u003cb\u003eJames D Brierley\u003c\/b\u003e, BSc, MB, FRCP, FRCR, FRCPC; Professor, Department of Radiation Oncology, Princess Margaret Cancer Centre \/ University of Toronto, Toronto, Ontario, Canada.\u003c\/p\u003e \u003cp\u003e\u003cb\u003eAnne W. M. Lee\u003c\/b\u003e, MD; Clinical Professor, Department of Clinical Oncology, The University of Hong Kong, Hong Kong, China.\u003c\/p\u003e \u003cp\u003e\u003cb\u003eElisabeth van Eycken\u003c\/b\u003e, MD; Director, Belgium Cancer Registry, Brussels, Belgium.\u003c\/p\u003e  \u003cp\u003e\u003cb\u003eTNM Supplement\u003c\/b\u003e A Commentary on Uniform Use \u003c\/p\u003e\u003cp\u003eFifth Edition \u003c\/p\u003e\u003cp\u003eThe Union for International Cancer Control's (UICC) TNM classification system is the most widely used cancer classification and staging system in the world. It is used to describe the anatomical extent of disease and is essential to patient care, research and cancer control. \u003c\/p\u003e\u003cp\u003eThis fifth edition of the \u003ci\u003eTNM Supplement: A Commentary on Uniform Use\u003c\/i\u003e offers practitioners a wealth of material intended to complement the system's day-to-day use. The volume features: \u003c\/p\u003e\u003cul\u003e \u003cli\u003eUpdated definitions of terms used in cancer staging.\u003c\/li\u003e \u003cli\u003eNew sections on carcinomas of the thymus, sarcomas of the spine and pelvis, and soft tissue sarcomas of the head and neck, as well as comprehensive updates to sections on head and neck carcinomas, carcinomas of the lung and neuroendocrine tumours.\u003c\/li\u003e \u003cli\u003eFrequently asked questions from the UICC helpdesk.\u003c\/li\u003e \u003c\/ul\u003e \u003cp\u003eThe supplement may be treated as a companion text to the recent eighth edition of the\u003ci\u003e TNM Classification of Malignant Tumours\u003c\/i\u003e (978-1-119-26357-9), supporting the correct and uniform application of the TNM classification system. The\u003ci\u003e TNM Supplement\u003c\/i\u003e can also be utilised as a standalone book, providing explanations and examples to answer many questions that arise during the daily use of the TNM cancer classification and staging system, particularly in unusual cases.\u003c\/p\u003e","brand":"Wiley-Blackwell","offers":[{"title":"Default Title","offer_id":47990393340133,"sku":"NP9781119263937","price":51.95,"currency_code":"USD","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1842\/7735\/files\/9781119263937.jpg?v=1761787648","url":"https:\/\/k12savings.com\/products\/tnm-supplement-isbn-9781119263937","provider":"K12savings","version":"1.0","type":"link"}